Compare GROY & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | ABCL |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | GROY | ABCL |
|---|---|---|
| Price | $3.83 | $3.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.90 | ★ $8.40 |
| AVG Volume (30 Days) | 2.3M | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $145.80 | N/A |
| Revenue Next Year | $60.03 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $1.43 | $1.94 |
| 52 Week High | $5.45 | $6.52 |
| Indicator | GROY | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 65.31 |
| Support Level | $3.25 | $3.91 |
| Resistance Level | $3.83 | $4.93 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 79.46 | 86.14 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.